The Journal of Immunology, Vol 151, Issue 3 1646-1653, Copyright © 1993 by American Association of Immunologists

ARTICLES

Induction of HIVMN neutralizing antibodies in primates using a prime- boost regimen of hybrid synthetic gp120 envelope peptides

BF Haynes, JV Torres, AJ Langlois, DP Bolognesi, MB Gardner, TJ Palker, RM Scearce, DM Jones, MA Moody and C McDanal
Department of Medicine, Duke University Arthritis Center, Durham, NC.

We have tested synthetic peptides composed of Th (T1) and V3 loop B cell neutralizing determinants [SP10 MN(A)] of HIVMN gp120 and the fusogenic (F) domain of gp41 as immunogens in rhesus monkeys. After two immunizations with either HIV env peptide T1-SP10 MN(A) or F-T1-SP10 MN(A), rhesus monkey serum neutralization titers against the HIVMN isolate ranged from 1:160 to 1:1400, and in cell-cell syncytium inhibition assay ranged from 1:20 to 1:80. However, in contrast to animals immunized with T1-SP10 MN(A), animals immunized twice with F-T1- SP10 MN(A) had no rise in anti-gp120 and neutralizing antibodies with an additional immunization with F-T1-SP10 MN(A) peptide. One of 4 rhesus monkeys (18987) had anti-HIVMN antibodies that cross-neutralized divergent HIV isolates HIVIIIB and HIVRF. Serum from animal 18987 neutralized 5 of 10 HIV isolates tested, and neutralizing activity against HIVIIIB of 18987 serum was absorbed with the conserved gp120 loop V3 sequence IGPGRAF. Anti-HIV neutralizing antibodies were boosted after a 6-mo rest by 500 micrograms of T1-SP10 MN(A) in 4 of 4 animals previously immunized with T1-SP10 MN(A) and in 2 of 2 animals previously immunized with F-T1-SP10 MN(A). However, immunization after 6-mo rest of animal 18987 with 500 micrograms of T1-SP10 MN(A) peptide, although boosting anti-HIVMN neutralizing antibodies, selectively did not boost cross-neutralizing anti-HIVIIIB antibodies. Thus, synthetic peptides containing T and B cell epitopes of HIV gp120 can induce high levels of anti-HIVMN neutralizing antibodies in primates.

This article has been cited by other articles:

				N. L. Letvin, S. Robinson, D. Rohne, M. K. Axthelm, J. W. Fanton, M. Bilska, T. J. Palker, H.-X. Liao, B. F. Haynes, and D. C. Montefiori Vaccine-Elicited V3 Loop-Specific Antibodies in Rhesus Monkeys and Control of a Simian-Human Immunodeficiency Virus Expressing a Primary Patient Human Immunodeficiency Virus Type 1 Isolate Envelope J. Virol., May 1, 2001; 75(9): 4165 - 4175. [Abstract] [Full Text]

				H.-X. Liao, B. Etemad-Moghadam, D. C. Montefiori, Y. Sun, J. Sodroski, R. M. Scearce, R. W. Doms, J. R. Thomasch, S. Robinson, N. L. Letvin, et al. Induction of Antibodies in Guinea Pigs and Rhesus Monkeys against the Human Immunodeficiency Virus Type 1 Envelope: Neutralization of Nonpathogenic and Pathogenic Primary Isolate Simian/Human Immunodeficiency Virus Strains J. Virol., January 1, 2000; 74(1): 254 - 263. [Abstract] [Full Text]

				H. M. Vu, D. Myers, R. de Lorimier, T. J. Matthews, M. A. Moody, C. Heinly, J. V. Torres, B. F. Haynes, and L. Spicer Nuclear Magnetic Resonance Analysis of Solution Conformations in C4-V3 Hybrid Peptides Derived from Human Immunodeficiency Virus (HIV) Type 1 gp120: Relation to Specificity of Peptide-Induced Anti-HIV Neutralizing Antibodies J. Virol., January 1, 1999; 73(1): 746 - 750. [Abstract] [Full Text] [PDF]

				J. D. Ahlers, T. Takeshita, C. D. Pendleton, and J. A. Berzofsky Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence PNAS, September 30, 1997; 94(20): 10856 - 10861. [Abstract] [Full Text] [PDF]